Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-risk Myelodysplastic Syndromes”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01546038
What this trial is testing

Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia
Pfizer 255
Not applicableStudy completedNCT00014235
What this trial is testing

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia/Transient Myeloproliferative DisorderAcute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in Remission+74 more
Fred Hutchinson Cancer Center 160
Testing effectiveness (Phase 2)Ended earlyNCT00113321
What this trial is testing

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Ended earlyNCT02240706
What this trial is testing

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Boehringer Ingelheim 27
Large-scale testing (Phase 3)UnknownNCT00043134
What this trial is testing

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
European Organisation for Research and Treatment of Cancer - EORTC 220
Testing effectiveness (Phase 2)Study completedNCT02610777
What this trial is testing

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Millennium Pharmaceuticals, Inc. 120
Testing effectiveness (Phase 2)Looking for participantsNCT01515527
What this trial is testing

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 160
Testing effectiveness (Phase 2)Looking for participantsNCT05365035
What this trial is testing

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Who this might be right for
Myelodysplastic SyndromesMyeloproliferative Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT07052006
What this trial is testing

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

Who this might be right for
Myelodysplastic SyndromeAnemia in Myelodysplastic Syndromes
Halia Therapeutics, Inc. 37
Testing effectiveness (Phase 2)Study completedNCT00455910
What this trial is testing

Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 112
Not applicableStudy completedNCT07008820
What this trial is testing

Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan

Who this might be right for
Myelodysplastic Syndrome (MDS)
Bristol-Myers Squibb 56
Testing effectiveness (Phase 2)Study completedNCT02335268
What this trial is testing

Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia

Who this might be right for
Myelodysplastic Syndromes
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 77
Testing effectiveness (Phase 2)Study completedNCT03502668
What this trial is testing

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Who this might be right for
Myelodysplastic Syndromes
Taiho Oncology, Inc. 160
Testing effectiveness (Phase 2)Ended earlyNCT02928419
What this trial is testing

Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q

Who this might be right for
Myelodysplastic Syndromes
Associazione Qol-one 2
Testing effectiveness (Phase 2)Study completedNCT00940602
What this trial is testing

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 225
Testing effectiveness (Phase 2)Ended earlyNCT03920657
What this trial is testing

Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

Who this might be right for
Myelodysplastic Syndromes
Fondazione Italiana Sindromi Mielodisplastiche-ETS 11
Testing effectiveness (Phase 2)Looking for participantsNCT04239157
What this trial is testing

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Chronic Myelomonocytic Leukemia+3 more
M.D. Anderson Cancer Center 76
Testing effectiveness (Phase 2)UnknownNCT01894477
What this trial is testing

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia in RemissionChronic Myelomonocytic LeukemiaMinimal Residual Disease+3 more
Fred Hutchinson Cancer Center 102
Early research (Phase 1)UnknownNCT04429191
What this trial is testing

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Who this might be right for
MYELODYSPLASTIC SYNDROME; MDSACUTE MYELOID LEUKEMIA; AML
Jasper Therapeutics, Inc. 40
Testing effectiveness (Phase 2)UnknownNCT00304720
What this trial is testing

Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor

Who this might be right for
Multiple MyelomaLymphomaAcute Myelogenous Leukemia+2 more
Colorado Blood Cancer Institute 40
Next Page